Vertex Pharmaceuticals reported quarterly earnings of $4.76 per share, below analyst estimates ranging from $4.82 to $4.92, compared with $4.80 a year earlier. Revenue reached $3.44 billion, exceeding the $3.42 billion estimate and rising 11.8% from $3.08 billion in the same quarter a year earlier. Cystic fibrosis drug sales and growth in Casgevy and Journavx drove the revenue increase. The company raised its 2026 sales outlook following its third-quarter revenue performance.
The company reported quarterly revenue of $3.44 billion driven by cystic fibrosis drug sales, despite an earnings miss of $4.76 per share against estimates of $4.92.
Read the full storyVertex Pharmaceuticals reported Q3 earnings of $4.76 per share, falling short of the $4.92 per share consensus estimate provided by analysts.
The results cover the company's Q3 FY2026. EPS came in below analysts' estimate by 1.2%; revenue above the estimate by 0.6%.